Sensus Healthcare, Inc. (SRTS)

Over the past six months, Sensus Healthcare filed a lawsuit against SkinCure Oncology for breach of contract. The company posted a loss for 2025 and outlined its growth strategy in its 10-K filing. Sensus Healthcare introduced "Sensus Link" to enhance the SRT-100™ installed base. Director Eric Sachetta bought 2,000 shares at $3.81. Sensus launched "Sensus Healthcare Financial Services" to facilitate customer acquisition of SRT technology. The company reported its Fourth Quarter 2025 financial results, highlighting a profit swing to a loss and a fall in revenue for 2025, missing analyst estimates, resulting in a stock price drop. Sensus Healthcare appointed Carr, Riggs & Ingram as its new auditor. The company reported Third Quarter 2025 financial results, with revenues of $6.9 million and a net loss of $0.9 million, or $0.06 per share.

Sensus Healthcare's revenues have shown seasonality, with Q3 2023 revenues reflecting seasonality and macroeconomic conditions. Conversely, Q4 2023 revenues were up threefold sequentially, also reflecting ongoing customer adjustments to macroeconomic conditions. Demand for their products and services can fluctuate throughout the year, with the third quarter potentially being weaker and the fourth quarter showing stronger performance.

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive and minimally-invasive treatments for skin conditions, focusing on superficial radiotherapy (SRT and IG-SRT) using low-energy X-rays. The company operates in the Healthcare sector, specifically in the Medical Devices and Surgical and Medical Instrument Manufacturing industries, developing and manufacturing SRT systems for treating non-melanoma skin cancers and other skin conditions like keloids. Its major products include the SRT-100™, SRT-100 Vision™, SRT-100+™, Sentinel service program, and a Transdermal Infusion system. The company also distributes laser devices for various applications.

Sensus Healthcare, Inc. is headquartered in Boca Raton, Florida, United States, with a significant portion of its revenue generated from U.S. customers. The company also has an expanding international presence, including shipments of SRT systems to international markets like China.

Sensus Healthcare has received positive recognition, being named to TIME's list of America's Growth Leaders of 2026. Analysts generally have a "Moderate Buy" to "Strong Buy" consensus rating for the stock. However, the company's reputation has faced some challenges due to analyst concerns regarding execution risks and quarterly volatility. The company missed analyst estimates in its Q4 2025 earnings report, showing a significant decline in revenue and a swing to a net loss. The recent lawsuit filed by Sensus Healthcare against SkinCure Oncology for breach of contract could also affect its brand image.

The ownership structure of Sensus Healthcare (SRTS) stock includes institutional, insider, and retail investors. Institutional investors own approximately 16.42% to 21.55% of the company's stock. Insiders own about 9.13% to 32.61% of the stock. Retail and individual investors hold a significant portion, estimated around 69.32%. Major institutional owners include Vanguard Group Inc., Pacific Ridge Capital Partners, LLC, and Dimensional Fund Advisors Lp. Key individual insider owners include Joseph C. Sardano (CEO), Kalman Fishman, and Richard Golin.